Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physicianreported spondylitis'?' by Siebert and Marzo-Ortega.

Authors :: Braun J
Landewé RB
Source :: Annals of the rheumatic diseases [Ann Rheum Dis] 2023 Aug; Vol. 82 (8), pp. e186. Date of Electronic Publication: 2021 Nov 29.
Publication Year :: 2023
Abstract: Competing Interests: Competing interests: None declared.

Subjects :: Humans
Randomized Controlled Trials as Topic
Arthritis, Psoriatic drug therapy
Spondylarthritis drug therapy
Spondylitis
Axial Spondyloarthritis
Spondylitis, Ankylosing

Full Text Access

Tools